Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Hydra Biosciences and Cubist to develop novel ion channel drugs for pain
December 2009
SHARING OPTIONS:

CAMBRIDGE, Mass.Hydra Biosciences and Cubist Pharmaceuticals Inc. announced in November a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra's research and development program for ion channel compounds that target the TRPA1 receptor, which is believed to have an important role in pain management. Cubist will support Hydra's internal development on the TRPA1 program by providing $5 million in R&D funding for two years, with an option to renew. Hydra will receives a $5 million upfront payment from Cubist. Hydra is also eligible for potential development milestones and royalties on products produced from the joint program.

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.